At 10 am on April 11, 2012, Shenzhen Yishi Kangning Biotechnology Co., Ltd. held a grand opening ceremony and officially settled in Yuanzheng Innovation Building.

         ISKCON will scientifically and standardizedly develop ACTL targeted anti-tumor cell immune technology and its preparation product group, making ACTL, an international innovative technology, one of the mainstream tumor treatment methods approved by the government, supported by doctors and benefiting patients. After that, the representative of the company promoters and the general manager cut the ribbon for the company. The visiting guests and company employees visited the company's newly opened international advanced production and experimental facilities.